Hypertension is a common condition that, if not detected and treated early, can easily lead to cardiovascular events, stroke, kidney failure, and even death. The new guideline’s recommended starting treatment blood pressure levels, treatment goals, and therapeutic use are supported by rigorous evidence. The guidelines were developed by a panel of experts from the Eighth Joint National Committee Association. The new guidelines answer three frequently asked questions: When to start antihypertensive therapy The expert panel provides clarity on the blood pressure level at which treatment needs to be started. The guidelines recommend that antihypertensive therapy should be initiated in people over 60 years of age with blood pressure of 150/90; the target values for treatment are as described above. However, the panel emphasized that the new guidelines do not redefine hypertension, and that the level of hypertension previously defined by Joint National Committee 7 (>=140/90 mm Hg) remains valid. People with blood pressure in this range should be treated with lifestyle interventions. The new guideline answers to these three questions are generally summarized as follows: the target value for the treatment of hypertension should be 150/90 mm Hg in older hypertensive patients over the age of 60 years, and diastolic blood pressure should be less than 90 mm Hg in hypertensive patients aged 30-59 years. There is also no evidence to support the target values for diastolic blood pressure in patients with hypertension under 30 years of age. In addition, for patients under 60 years of age with hypertension combined with diabetes mellitus or hypertension combined with non-diabetic chronic kidney disease (CKD), the guideline recommended therapeutic targets are consistent with those for the general hypertensive population under 60 years of age. For non-black hypertensive patients (including those with co-morbid diabetes), the guidelines recommend ACEI drugs, ARBs, calcium channel blockers, and thiazide diuretics as starting medications; for black hypertensive patients (including those with co-morbid diabetes), calcium channel blockers or thiazide diuretics as starting medications. In addition, the guidelines recommend the use of ACEI drugs or ARBs to improve renal function at the beginning or continuation of antihypertensive therapy for hypertensive patients with comorbid chronic kidney disease.